INVITROCUE®
Transforming bioanalytics

PRECISION ONCOLOGY: THE FUTURE OF PERSONALIZED CANCER TREATMENT

1st October 2018

TIME	PROGRAMME
8:15 – 8:50 am	REGISTRATION *Please be seated by 8.50 am
9:00 – 9:30 am	WELCOME ADDRESS **Dr. Steven Fang** Co-Founder & Executive Director Invitrocue Pte Ltd
9:30 - 10:30 am	**Phenotype driven oncology and the clinical impact** **Assoc. Prof. Gopal Iyer** MBBS (NUS), PhD (Cambridge), FRCSEd, FAMS Senior Consultant National Cancer Centre Singapore Division of Surgical Oncology
10:30 – 11:00 am	TEA BREAK
11:00 am - noon	**The clinical utility of precision medicine in breast cancer** **Prof. Louis Chow Wing Cheong** MBBS (HK), FHKAM (Surgery), FHKAM (Radiology), MS (HK), FCSHK, FRCS (Glasgow) Medical Director Comprehensive Centre for Breast Diseases UNIMED Medical Institute in Hong Kong
Noon – 1:30 pm	LUNCH
1:30 - 2:15 pm	**Wnt signaling in regulating mammary stem cells and breast cancer** **Prof. Arial Yi Zeng, Ph.D.** Principal Investigator, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
2:15 - 3:15 pm	**Drug evaluation in 4D: low throughput/high value?** **Prof. Alastair Stewart, Ph.D.** Co-Director Department of Pharmacology and Therapeutics School of Biomedical Sciences Faculty of Medicine, Dentistry and Health Sciences University of Melbourne
3:15 – 3:45 pm	CLOSING REMARKS **Dr. Andreas Lindner** CEO, Invitrocue Europe AG

ABOUT INVITROCUE

Invitrocue (ASX:IVQ) is a bioanalytics company spun out of Singapore's Agency For Science, Technology and Research (ASTAR) whose products and services help predict the effect of drugs in human tissue before they are used in people. The company was founded in 2012 to commercialise '3D cell culture' technology developed by Professor Hanry Yu and colleagues at ASTAR's Institute of Bioengineering and Nanotechnology in Singapore.

Dr Steven Fang is co-founder of Invitrocue together with Professor Hanry Yu. Dr Steven Fang has a wealth of experience in the pharmaceutical and life sciences fields, most notably as founder and former CEO of the Cordlife Group (2001 – 2012), founder and CEO of Capbridge (since 2014), and as partner at Clearbridge Accelerator (since 2013).

Invitrocue uses its 3D cell culture technology to develop in vitro (in-lab) liver models to improve toxicology testing. Invitrocue is also using its expertise and know-how in 3D cell culture to grow patient-derived cancer cells in its scaffolds and other platforms to test them against a range of cancer drugs. This is being offered through Invitrocue's Onco-PDO 'precision oncology' clinical service, a tool for selecting the right cancer drugs from an in vitro model of a patient's tumour.

Invitrocue is headquartered in Singapore, with operations in Australia, New Zealand, China, Hong Kong, Germany, and Northern Ireland.